Overview

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

The main purposes of this study are to learn how effective the study drug combinations are in treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Parker Institute for Cancer Immunotherapy

Collaborators:

Apexigen, Inc.
Bristol-Myers Squibb
Cancer Research Institute, New York City

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Gemcitabine
Nivolumab
Paclitaxel